title: FDA panel votes to pull Avastin in breast cancer, again.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D005260:Female; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab